Vincent Romanet

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer
Published: June 17, 2024

QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.

QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.

Journal: Journal of pharmacokinetics and pharmacodynamics
Published: May 14, 2024

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Journal: Nature
Published: July 26, 2023

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer
Published: May 22, 2023

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.

Journal: Journal of mammary gland biology and neoplasia
Published: October 06, 2022

INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.

INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.

Journal: Nature cancer
Published: July 25, 2022

HistoNet: A Deep Learning-Based Model of Normal Histology.

HistoNet: A Deep Learning-Based Model of Normal Histology.

Journal: Toxicologic pathology
Published: March 03, 2021

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.

Journal: PloS one
Published: April 10, 2019

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Journal: Cancer research
Published: February 02, 2018

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 08, 2017

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.

Journal: Blood
Published: December 22, 2015

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Journal: Cancer discovery
Published: January 10, 2015
Showing 1-12 of 23

Last Updated: 09/26/2026